DDInter342 DDInter875
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stavudine
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Abatacept
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Tildrakizumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Stavudine
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Certolizumab pegol may lead to a major life threatening interaction when taken with Abatacept
Certolizumab pegol may lead to a major life threatening interaction when taken with Tildrakizumab